Contact this trialFirst, we need to learn more about you.
Small Molecule Inhibitor
Capmatinib +2 More for Non-Small Cell Lung Cancer
Recruiting0 awardsPhase 2
Montreal, Quebec
This trial is testing a combination of two drugs, capmatinib and spartalizumab, versus capmatinib and placebo as a potential treatment for NSCLC. The trial is double-blind and placebo-controlled, meaning that neither the patients nor the researchers will know who is receiving the active treatment and who is receiving the placebo. The trial is also randomized, meaning that patients will be assigned to the treatment groups by chance. This is a phase II trial, which means that the researchers are primarily interested in whether the treatment is effective and safe, rather than whether it is better than the current standard of care.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.